Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Anrikefon in Renal Impairment
NCT05947097Phase 1Unknown
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hsk21542 in chronic kidney disease-associated pruritus (CKD-aP) and postoperative pain (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Time and 1 more. Status: unknown.
02
Drugs
hsk21542
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)postoperative pain
Beyond the preview
Go deeper on NCT05947097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947097.